Prognostic value of HER2 discordance between primary and metastatic or recurrent breast cancer: A systematic review and meta-analysis

Shunsuke Nakatani, Takuya Hayashi, Aoi Hosaka, Hideki Maeda

Open source

DOI
10.1016/j.critrevonc.2025.105016
Published
2026-01
Container
Critical Reviews in Oncology/Hematology
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.critrevonc.2025.105016,
  title = {Prognostic value of HER2 discordance between primary and metastatic or recurrent breast cancer: A systematic review and meta-analysis},
  author = {Shunsuke Nakatani and Takuya Hayashi and Aoi Hosaka and Hideki Maeda},
  year = {2026},
  journal = {Critical Reviews in Oncology/Hematology},
  doi = {10.1016/j.critrevonc.2025.105016},
  url = {https://doi.org/10.1016/j.critrevonc.2025.105016}
}

RIS

TY  - JOUR
TI  - Prognostic value of HER2 discordance between primary and metastatic or recurrent breast cancer: A systematic review and meta-analysis
AU  - Shunsuke Nakatani
AU  - Takuya Hayashi
AU  - Aoi Hosaka
AU  - Hideki Maeda
PY  - 2026
JO  - Critical Reviews in Oncology/Hematology
DO  - 10.1016/j.critrevonc.2025.105016
UR  - https://doi.org/10.1016/j.critrevonc.2025.105016
ER  - 

APA

Nakatani, S., Hayashi, T., Hosaka, A., & Maeda, H. (2026). Prognostic value of HER2 discordance between primary and metastatic or recurrent breast cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. https://doi.org/10.1016/j.critrevonc.2025.105016

Source records